At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 in Subjects With Type 2 Diabetes in Japan
In Brief
A Phase 2 clinical trial evaluating Alogliptin, Voglibose, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 480 participants across 1 site.
Detailed Summary
The purpose of this study was to evaluate the dose-response relationships of alogliptin, once daily (QD) to an α-glucosidase inhibitor, three times daily (TID), to determine the optimal clinical dose for type 2 diabetic patients.
Study Details
Timeline
Interventions
Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.